Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
Latest quote
¥828
−¥8.00 · -0.96%
Regular session · JST · Market data may be delayed.
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
Day range
Current ¥828
52-week range
Current ¥828
Regular session · JST · Market data may be delayed.
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.
Day range
Current ¥828
52-week range
Current ¥828
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 4.94B JPY | 5.21B JPY | 4.77B JPY | 4.74B JPY | 3.95B JPY |
| Cost of goods sold | 3.08B JPY | 2.84B JPY | 2.89B JPY | 2.29B JPY | 1.91B JPY |
| Gross profit | 1.86B JPY | 2.37B JPY | 1.88B JPY | 2.45B JPY | 2.04B JPY |
| Selling, general, and administrative | 1.52B JPY | — | −1K JPY | 1.19B JPY | 1.07B JPY |
| Operating expenses | 1.52B JPY | 1.37B JPY | 1.28B JPY | 1.19B JPY | 1.07B JPY |
| Interest income | 4.42M JPY | 1.93M JPY | 651K JPY | 425K JPY | 273K JPY |
| Interest expense | 38.05M JPY | 30.07M JPY | 22.87M JPY | 32.47M JPY | 38.94M JPY |
| Depreciation and amortization | 396.15M JPY | 360.97M JPY | 299.63M JPY | 167.59M JPY | 179.06M JPY |
| Operating income | 341.54M JPY | 991.14M JPY | 596.82M JPY | 1.27B JPY | 969.58M JPY |
| Net income | 251.02M JPY | 794.76M JPY | 384M JPY | 829.79M JPY | 587.68M JPY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
¥24.00
2025 complete year+115.1% since 2024
2026 partial: ¥10.00
¥11.1559
2,024
¥24.00
2,025
¥10.00
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Mar 30, 2027 | ¥10.00Annual | Mar 31, 2027 | Mar 30, 2027 |
Dividend | Mar 30, 2026 | ¥10.00Annual | Mar 31, 2026 | Jun 29, 2026 |
Dividend | Mar 28, 2025 | ¥24.00Annual | Mar 31, 2025 | Jun 30, 2025 |
Dividend | Mar 28, 2024 | ¥11.1559Annual | Mar 31, 2024 | Jul 1, 2024 |
Ex-dividend Mar 30, 2027
¥10.00
Annual
Record Mar 31, 2027 · Payment Mar 30, 2027
Ex-dividend Mar 30, 2026
¥10.00
Annual
Record Mar 31, 2026 · Payment Jun 29, 2026
Ex-dividend Mar 28, 2025
¥24.00
Annual
Record Mar 31, 2025 · Payment Jun 30, 2025
Ex-dividend Mar 28, 2024
¥11.1559
Annual
Record Mar 31, 2024 · Payment Jul 1, 2024
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.